Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease.
about
Intracellular cleavage of amyloid β by a viral protease NIa prevents amyloid β-mediated cytotoxicityBrain amyloid-β oligomers in ageing and Alzheimer's disease.2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.Associating a negatively charged GdDOTA-derivative to the Pittsburgh compound B for targeting Aβ amyloid aggregates.Loss of serum IGF-I input to the brain as an early biomarker of disease onset in Alzheimer mice.SELDI-TOF-MS proteomic profiling of serum, urine, and amniotic fluid in neural tube defects.Soluble Aβ oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes.A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study.Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide.Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples.Time-dependent changes in gene expression induced by secreted amyloid precursor protein-alpha in the rat hippocampusA monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Aβ.Amyloid-β oligomers stimulate microglia through a tyrosine kinase dependent mechanism.A novel pathway for amyloids self-assembly in aggregates at nanomolar concentration mediated by the interaction with surfaces.Diagnosing Alzheimer's disease: are we any nearer to useful biomarker-based, non-invasive tests?Profiling for novel proteomics biomarkers in neurodevelopmental disorders.Mechanisms of neural and behavioral dysfunction in Alzheimer's disease.Aggregation of amyloids in a cellular context: modelling and experiment.The role of metallobiology and amyloid-β peptides in Alzheimer's disease.Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease.Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes.Biological metals and metal-targeting compounds in major neurodegenerative diseases.An Account of Amyloid Oligomers: Facts and Figures Obtained from Experiments and Simulations.Protein folding, misfolding and aggregation: The importance of two-electron stabilizing interactions.The Aggregation Paths and Products of Aβ42 Dimers Are Distinct from Those of the Aβ42 Monomer.An anemia of Alzheimer's disease.Anti-Aβ antibody target engagement: a response to Siemers et al.Guanidine hydrochloride denaturation of dopamine-induced α-synuclein oligomers: a small-angle X-ray scattering study.Zinc-induced dimerization of the amyloid-β metal-binding domain 1-16 is mediated by residues 11-14.Aβ dimers differ from monomers in structural propensity, aggregation paths and population of synaptotoxic assemblies.The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death.Synthetic dityrosine-linked β-amyloid dimers form stable, soluble, neurotoxic oligomersCopper Redox Cycling Inhibits Aβ Fibre Formation and Promotes Fibre Fragmentation, while Generating a Dityrosine Aβ Dimer
P2860
Q27324934-2DB2E454-08C1-479E-A87C-E3BB7B123C20Q30539133-86F8B2C2-FE44-4240-A9E8-E03A703D791EQ30971403-00BE0604-CBA7-4A10-AA00-45E10394F566Q31028845-8E40D481-B9E3-4D36-B616-C34F4505A286Q33647486-C82D1D5E-E600-4243-89AA-7FFBB1630B6AQ33940289-79A42905-5A8F-444E-9FA2-24649ED6B83FQ34031193-8E385FDE-CA75-44DC-9F1D-BAEB9018AA48Q34341870-E91E36FD-320A-4902-91E3-A9E60778CB58Q34419108-461A6FFE-B958-4889-91B8-09B405676541Q34500145-27268C84-EBA5-489F-A037-4CA970B33D3FQ34564863-0E7D235C-F03E-400A-994B-C3A1BB9AFD6EQ34761829-DA6CB098-8EF6-4977-A2ED-D9F934FC496AQ35216697-38D57DD1-22B1-4D45-996B-319D3FCBFCF8Q35803328-74412758-191A-44F9-A3F7-A327B22FEDF5Q36327854-CE9DD982-D81E-4FF2-9577-A0B74E416733Q36915254-0CD9052D-035C-4DF6-90E8-9A3F9783A2C2Q37844157-D0310FC2-49A7-4DE0-86C9-0A76A888C607Q37855656-4F2B95BB-F9DA-4A9E-BA40-36C2DF36BBDAQ37922207-514D8508-4EFD-4C65-95F7-F004A20DA2F5Q37961769-8397C070-AC3E-4040-963B-BF161DAF2D93Q38016898-F925A9BE-9C47-4A77-8ED0-C1BB135E66D4Q38125769-7EEA3B96-A464-452D-89D2-71C00BBF0C1AQ38237519-AE28873B-C1B8-4B51-96FA-E839B3E80A90Q38748337-E6F8F63A-1FA5-4B20-878A-D32054B93093Q41702344-45F09F1D-744B-4177-969F-2F47BD0340F7Q43020455-30362B69-8ACE-488E-AD98-6CB8C44AD0C8Q45005043-54A17D0F-100D-4C9F-AF07-AD7399EB8079Q50628062-78F9C4F3-E9CE-478F-954A-6A3684482D46Q50939945-F85F8255-CF9E-45FA-B710-CEA580E1F770Q53317059-3C761D9C-7300-4DB2-8F0D-38B9C2F1C0E2Q53352144-52AEEB18-8C77-402B-A085-BF9C5CC9E2D8Q55177411-869721AE-1CF0-472D-81F7-ED37539C791EQ57838159-76E17064-0325-4048-A591-73994885B89FQ58577688-9696D2EB-7D3B-4B2A-B083-09C7547CFD48
P2860
Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease.
@en
Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease.
@nl
type
label
Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease.
@en
Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease.
@nl
prefLabel
Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease.
@en
Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease.
@nl
P2093
P50
P1476
Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease.
@en
P2093
Christopher C Rowe
Colin L Masters
Kevin J Barnham
Keyla A Perez
Victor L Villemagne
P304
P356
10.1523/JNEUROSCI.5180-09.2010
P407
P50
P577
2010-05-01T00:00:00Z